Document Detail


Practical tip: Precooling topical calcineurin inhibitors tube; reduces burning sensation.
MedLine Citation:
PMID:  20409423     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Burning sensation at the site of application is the most common side effect of topical calcineurin inhibitors and is considered the most common reasons for premature discontinuation. Here, we analyze the possible mechanism(s) and offer a simple practical tip to mitigate this adverse effect. Simple cooling of the tube, immediately before use, does reduce the burning sensation and enable most intolerant patients to use the medication comfortably. We also discuss the possible explanation(s) for the success of this maneuver.
Authors:
Sultan Al-Khenaizan
Related Documents :
11233373 - Balancing rationalities: gatekeeping in health care.
11123563 - Quality assessment in general practice trainers.
11984163 - Anthrax: is there a risk of cross-infection during endoscopy?
Publication Detail:
Type:  Journal Article     Date:  2010-04-15
Journal Detail:
Title:  Dermatology online journal     Volume:  16     ISSN:  1087-2108     ISO Abbreviation:  Dermatol. Online J.     Publication Date:  2010  
Date Detail:
Created Date:  2010-04-22     Completed Date:  2010-07-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9610776     Medline TA:  Dermatol Online J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  16     Citation Subset:  IM    
Affiliation:
College of Medicine, Division of Dermatology, Department of Medicine, King Abdulaziz Medical City, Riyadh, King Saud Bin Abdulaziz University for Health Sciences. salkhenaizan@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Calcineurin / antagonists & inhibitors*
Cold Temperature
Dermatitis, Atopic / drug therapy
Dermatologic Agents / administration & dosage,  adverse effects*
Humans
Pain / chemically induced,  prevention & control*
Tacrolimus / administration & dosage,  adverse effects*,  analogs & derivatives*
Chemical
Reg. No./Substance:
0/Dermatologic Agents; 0/pimecrolimus; 109581-93-3/Tacrolimus; EC 3.1.3.16/Calcineurin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Letter: Iatrogenic lipomatosis: a rare manifestation of treatment with a peroxisome proliferator-act...
Next Document:  Examining the etiology of associations between perceived parenting and adolescents' alcohol use: com...